LXRX Lexicon Pharmaceuticals Inc.

+0.05  (+4%)
Previous Close 1.32
Open 1.35
Price To Book -2.25
Market Cap 145,592,540
Shares 106,271,927
Volume 614,261
Short Ratio
Av. Daily Volume 1,361,088

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial also met primary endpoint - June 9, 2017.
Type 1 Diabetes
Phase 2 trial did not meet primary endpoint.
Type 1 Diabetes
CRL issued March 22, 2019.
Type 1 Diabetes
Approved February 28, 2017.
Telotristat etiprate (XERMELO)
Carcinoid Syndrome
SNY informed LXRX July 26, 2019 that it plans to terminate its agreement following insufficient efficacy across three Phase 3 trials. Presentation of new data due at EASD 16-20 September 2019.
Type 2 Diabetes
Phase 1b top-line data due 2H 2019.
Neuropathic pain
Phase 2a initiation of dosing announced March 15, 2019. Top-line data due 2020.
Telotristat ethyl - TELE-ABC
Biliary tract cancer (BTC)

Latest News

  1. Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
  2. Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes
  3. Edited Transcript of LXRX earnings conference call or presentation 31-Jul-19 12:00pm GMT
  4. Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
  5. Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
  6. Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update
  7. Lexicon Pharmaceuticals Announces Date Change for Second Quarter 2019 Financial Results Conference Call and Webcast to July 31, 2019
  8. Why Cooper Tire & Rubber, Insperity, and Lexicon Pharmaceuticals Slumped Today
  9. Here's Why Lexicon Pharmaceuticals Is Collapsing Today
  10. Lexicon's stock loses more than half its value after Sanofi's notice to end alliance
  11. Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
  12. UPDATE 1-Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
  13. Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program
  14. Sanofi ends partnership with Lexicon to develop diabetes drug
  15. How Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Can Impact Your Portfolio Volatility
  16. Lexicon Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on August 1, 2019
  17. Lexicon Pharmaceuticals (LXRX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
  18. AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes
  19. Here is What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX)
  20. Should You Be Pleased About The CEO Pay At Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX)